120 likes | 206 Views
STRATINC Interreg III C: Tenerife meeting. The Oslo Biotech Cluster. Knut Halvorsen Manager Oslo Teknopol IKS 7th and 8 th April 2005. Background. High indirect independency on petroleum (”Kuwait” economy) Science based region (50% of Norways R&D) Low innovation rate (2 – 3% from R&D).
E N D
STRATINC Interreg III C: Tenerife meeting The Oslo Biotech Cluster Knut Halvorsen Manager Oslo Teknopol IKS 7th and 8 th April 2005
Background • High indirect independency on petroleum (”Kuwait” economy) • Science based region (50% of Norways R&D) • Low innovation rate (2 – 3% from R&D)
The process – RITTS • RITTS – Negotiations: Fall 1998 • Stage 0: Through 1999: Concensus • Stage 1: Though 2000 : Analysis • Stage 2: First half 2001: Implementation • Result: June 2001: Final report • Methodology: Internal and external experts • Organisation: Integrated in the main decision structure in the region.
Defintion: Technopole • « Supporting a territorial development policy based on innovation, a technopole favours cross-fertilisation. Creation of innovative activities, animation and networking of competences, territorial marketing, are the components of the technopolitan dynamics » (France Technopoles Entreprises Innovation)
Oslo Teknopol - organisation • Owned by Oslo and County of Akershus • 13 employees (social sciences) • Budget of NOK 16 mill. • Theoretical approach: Clusters • Strategy: Technopole • Methodology: Governance • Vision: Oslo Teknopol shall – in cooperation with others – work towards making the Osloregion one of the most innovative regions in Europa by 2010.
The strategies: ”Bottom up” and Clusters • Martime, • Energy and Environment • ICT • Life Science, • Art and Design
Clusters, interfaces and facilitators Energy & environmental technology Maritime Information & communication technology Art, design, film & architecture Life science TTO Innovation companies Innovation networks Reasearch Parks & incubators
Life Science in the Oslo region – key players Symbols: Universities/higher education insitutions: 3 University hospitals: 5 Resarch instiutions including Centres of Excellence: 10 Science Parks: 2 Commercial inst: 3 Companies: 1 157 Regional networks: 3 Norwegian Bioindustry Association Medcoast Scandinavia Oslo/Göteborg Medicon Valley Stockholm/Copenhagen
4. Life science Leder: Professor Kaare Norum MedCoast Scandinavia OptiNose AS Glaxo Smith Kline Clavis Pharma Astra Zeneca Dynal Biotech ASA GE – Vingmed Ultrasound GenoMar ASA Biomedisinsk Innovasjon Dag Dvergsten AS Birkeland Innovasjon PubGene Bioteknologisenteret i Oslo Interagon Norges Vetrinærhøgskole Sim Surgery Høgskolen i Akershus Radiumhospitalets Forskningsstifelse Fondsfinans OT ved Knut Halvorsen og Therese HolmThorvaldsen
Summary, challenges to be discussed • Complex institutional structure • Non codified knowledge • Do not share core business ideas • Trust (F2F meetings) • PSIPs is one of many tools.